| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
4
3
5
5
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
B+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 0.79 | 0.0 | 0.79 |
| Stocks | 95.08 | 0.0 | 95.08 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.0 | 1.29 | -1.29 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 5.43 | 0.0 | 5.43 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 21.82 | 8.67 |
| Gilead Sciences Inc | GILD | 36.53 | 8.39 |
| Biogen Idec Inc | BIIB | 46.43 | 6.63 |
| Celgene Corporation | CELG | 48.67 | 6.58 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 3.99 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.71 | 3.97 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 3.33 |
| Life Technologies Corp | LIFE | 50.05 | 3.15 |
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 2.62 |
| Illumina, Inc. | ILMN | 14.8 | 2.47 |
